Sara Francescon

461 total citations
9 papers, 262 citations indexed

About

Sara Francescon is a scholar working on Oncology, Toxicology and Economics and Econometrics. According to data from OpenAlex, Sara Francescon has authored 9 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 5 papers in Toxicology and 3 papers in Economics and Econometrics. Recurrent topics in Sara Francescon's work include Pharmacovigilance and Adverse Drug Reactions (5 papers), Biosimilars and Bioanalytical Methods (3 papers) and Pharmaceutical Economics and Policy (3 papers). Sara Francescon is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (5 papers), Biosimilars and Bioanalytical Methods (3 papers) and Pharmaceutical Economics and Policy (3 papers). Sara Francescon collaborates with scholars based in Italy and Ukraine. Sara Francescon's co-authors include Paolo Baldo, Giulia Fornasier, Roberto Leone, Jerry Polesel, Paolo De Paoli, Martina Taborelli, Giuseppe Corona, Sara Cecco and Alessandra Bearz and has published in prestigious journals such as Expert Opinion on Drug Safety, Advances in Therapy and International Journal of Clinical Pharmacy.

In The Last Decade

Sara Francescon

9 papers receiving 247 citations

Peers

Sara Francescon

TOXIC

ONCOL

IMMUN

EE

MB

Giulia Fornasier Italy

Gautier Paux France

Eizaburo Sueoka Japan

Christopher McMaster Australia

Chaozheng Zhou China

Eric Hung United States

Elita Poplavska Latvia

Marco Chiumente Italy

Gustavo Grampp United States

Shanthi Sivendran United States

Giulia Fornasier Italy

Sara Francescon

99 ×1.0

TOXIC

134 ×1.5

ONCOL

78 ×1.7

IMMUN

38 ×1.0

EE

51 ×1.4

MB

Citations per year, relative to Sara Francescon Sara Francescon (= 1×) peers Giulia Fornasier

Countries citing papers authored by Sara Francescon

Since Specialization

Citations

This map shows the geographic impact of Sara Francescon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Francescon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Francescon more than expected).

Fields of papers citing papers by Sara Francescon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Francescon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Francescon. The network helps show where Sara Francescon may publish in the future.

Co-authorship network of co-authors of Sara Francescon

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Francescon. A scholar is included among the top collaborators of Sara Francescon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Francescon. Sara Francescon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Francescon, Sara, et al.. (2020). Pharmacovigilance of anti-cancer medicines: opportunities and challenges. Expert Opinion on Drug Safety. 19(7). 849–860. 13 indexed citations

2.

Bearz, Alessandra, et al.. (2019). Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer. Recent Patents on Anti-Cancer Drug Discovery. 14(3). 242–257. 6 indexed citations

3.

Fornasier, Giulia, Sara Francescon, & Paolo Baldo. (2018). An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review. Advances in Therapy. 35(10). 1497–1509. 75 indexed citations

4.

Francescon, Sara, Giulia Fornasier, & Paolo Baldo. (2018). EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies. International Journal of Clinical Pharmacy. 40(4). 778–782. 8 indexed citations

5.

Baldo, Paolo, et al.. (2018). Pharmacovigilance in oncology. International Journal of Clinical Pharmacy. 40(4). 832–841. 48 indexed citations

6.

Fornasier, Giulia, Martina Taborelli, Sara Francescon, et al.. (2018). Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. International Journal of Clinical Pharmacy. 40(4). 795–802. 32 indexed citations

7.

Baldo, Paolo, Sara Francescon, & Giulia Fornasier. (2018). Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology. International Journal of Clinical Pharmacy. 40(4). 748–753. 13 indexed citations

8.

Fornasier, Giulia, Sara Francescon, Roberto Leone, & Paolo Baldo. (2018). An historical overview over Pharmacovigilance. International Journal of Clinical Pharmacy. 40(4). 744–747. 65 indexed citations

9.

Francescon, Sara, Giulia Fornasier, & Paolo Baldo. (2016). Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations. Oncology and Therapy. 4(2). 173–182. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact